Voglibose
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | A10BF03 (WHO) |
Identifiers | |
| |
CAS Number |
83480-29-9 ![]() |
PubChem (CID) | 444020 |
DrugBank |
DB04878 ![]() |
ChemSpider |
392046 ![]() |
UNII |
S77P977AG8 ![]() |
KEGG |
D01665 ![]() |
ChEMBL |
CHEMBL476960 ![]() |
Chemical and physical data | |
Formula | C10H21NO7 |
Molar mass | 267.28 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was first launched in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.[1]
Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.
There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest.